oa Use of corticosteroids in COVID-19 patients vs. acute respiratory distress syndrome of other etiologies: Are there any differences?

References

1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary Manifestations of COVID-19. Nat Med. 2020 Jul; 26:(7):1017–32.
   [Google Scholar]
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20; 382:(8):727–33.
   [Google Scholar]
3. Organización Mundial de la Salud. Manejo clínico de la infección respiratoria aguda grave (IRAG) en caso de sospecha de COVID-19: orientaciones provisionales. [Internet]. 2020. Available from: https://apps.who.int/iris/handle/10665/331660 .
4. World Health Organization. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: interim guidance. [Internet]. 2019. Available from: https://apps.who.int/iris/handle/10665/178529 .
   [Google Scholar]
5. Belhadi D, Peiffer-Smadja N, Lescure FX, Yazdanpanah Y, Mentré F, Laouénan C. A Brief Review of Antiviral Drugs Evaluated in Registered Clinical Trials for COVID-19. Infectious Diseases (except HIV/AIDS); 2020 Mar;18.
   [Google Scholar]
6. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 Infection: The Perspectives on Immune Responses. Cell Death Differ. 2020 May; 27:(5):1451–4.
   [Google Scholar]
7. CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) [Internet]. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management177patients.html .
8. The Recovery Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. 2020 Jul 17;NEJMoa2021436.
   [Google Scholar]
9. Lewis SR, Pritchard MW, Thomas CM, Smith AF, . Pharmacological Agents for Adults with Acute Respiratory Distress Syndrome. Cochrane Emergency and Critical Care Group, editor. Cochrane Database Syst Rev. 2019 Jul23.
   [Google Scholar]
10. Liu J, Zhang S, Wu Z, Shang Y, Dong X, Li G, et al. Clinical Outcomes of COVID-19 in Wuhan, China: A Large Cohort Study. Ann Intensive Care. 2020 Dec; 10:(1):99.
    [Google Scholar]
11. Yang Q, Xie L, Zhang W, Zhao L, Wu H, Jiang J, et al. Analysis of the clinical Characteristics, Drug Treatments and Prognoses of 136 Patients with Coronavirus Disease 2019. J Clin Pharm Ther. 2020 Aug; 45:(4):609–16.
    [Google Scholar]
12. OMS. Brote de enfermedad por coronavirus (COVID-19) [Internet]. Organización Mundial de la Salud. 2020. Available from: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019 .
13. OMS. La OMS acoge con satisfacción los resultados de un ensayo sobre el uso de la dexametasona en el tratamiento de pacientes con COVID-19 en estado crítico. [Internet]. Organización Mundial de la Salud. 2020. Available from: https://www.who.int/es/news194room/detail/16-062020whowelcomespreliminaryresultsabout-dexamethasone-use-in195treating-critically-ill-covidpatients .
    [Google Scholar]
14. Meduri GU, Bridges L, Shih M C, Marik PE, Siemieniuk RAC, Kocak M. Prolonged Glucocorticoid Treatment is Associated with Improved ARDS Outcomes: Analysis of Individual Patients’ Data from Four Randomized Trials and Trial-level Meta-analysis of the Updated Literature. Intensive Care Med. 2016 May; 42:(5):829–40.
    [Google Scholar]
15. Dutta M, Dutta P, Medhi S, Borkakoty B, Biswas D, . Polymorphism of HLA Class I and Class II Alleles in Influenza A(H1N1) pdm09 Virus Infected Population of Assam, Northeast India. J Med Virol. 2018 May; 90:(5):854–60.
    [Google Scholar]
16. Prescott HC, Rice TW, . Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA. 2020 Oct 6; 324:(13):1292.
    [Google Scholar]
17. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med. 2021 Jul 17; 384:(8):693–704.
    [Google Scholar]